Loading
A phase 1/2 trial of Abexinostat in hodgkin lymphoma and non-hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients is a phase 1/2 interventional study registered as NCT04024696 by Xynomic Pharmaceuticals, Inc., with 12 participants enrolled, started 2020-01-08 and due to reach its primary completion in 2024-12-30. Interventions recorded: Abexinostat. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xynomic Pharmaceuticals, Abexinostat, Non-Hodgkin lymphoma (all types).
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/